The Capital Health Center for Digestive Health in New Jersey is currently enrolling patients in a clinical trial studying a new treatment method for acute alcoholic steatohepatitis (ASH), reports. The hospital’s Center for Liver Disease will be conducting Phase III trials for an extracorporeal liver assist device (ELAD), a new bio-artificial cell therapy, in which doctors allow a patient’s liver to regenerate on its own to a more stable condition until a transplant is possible. In previous trials, the ELAD method has been shown to increase survival rates in patients with acute liver failure and, in some cases, avoid unnecessary liver transplants. The study specifically targets AH, and is not intended for those with the hepatitis B or C viruses (HBV or HCV). Call (609) 537-5000 or go to for more information.

To read the article, click here.